Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Ocugen Korea

Keep exploring

Part of

Ocugen announced a regional partnership for OCU400 in Korea. All 1 developments

The entities involved

Ocugen
biopharmaceutical company

Nothing else this week.
Korea
region in East Asia
- Korea is leading a major initiative to develop the foundation for 6G by leveraging AI RAN technology, with Samsung Electronics and SK Telecom playing principal vendor roles.Mon 17:37
- Jamaica and Korea competed in the WorldSkills Competition.Mon 16:25

Coverage

Newest first; wire copies grouped

Aug 1GlobeNewswireOcugen Provides Business Update with Second Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clini